Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.42 |
| ▸ | NOS1 | P29475 | 5/20 | 0.42 |
| ▸ | NOS2 | P35228 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | INMT | O95050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865176 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL11237860 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL5865181 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL5098521 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL2382858 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL2382862 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL8268847 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL5865174 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL8446266 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 | |
| SCHEMBL9374974 | 1.00 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1474139-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | FONG TUNG M (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1474139-A4 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1482794-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1474139-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040122033-A1 | Combination therapy for the treatment of obesity | MERCK & CO., INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2003075660-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | MERCK & CO., INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003065983-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0069295-B1 | PROCESS FOR THE MANUFACTURE OF POSSIBLY CELLULAR POLYURETHANE OR POLYURETHANE-POLYUREA MOULDED ARTICLES | BASF Aktiengesellschaft (DE) | 1986-05-21 | — | — | EP | disclosed |
| US-4469653-A | AS POLYMERIZATION CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 1984-09-04 | — | — | US | disclosed |
| EP-0069295-A1 | Process for the manufacture of possibly cellular polyurethane or polyurethane-polyurea moulded articles | BASF Aktiengesellschaft (DE) | 1983-01-12 | — | — | EP | disclosed |
| US-4339381-A | 1,3-Alkylene-diazetidine-2,4-diones | THE UPJOHN COMPANY (US) | 1982-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122033-A1 | Combination therapy for the treatment of obesity | GPR119, GIPR, FABP6 | NOS3 312/4885NOS1 418/4885NOS2 348/4885 |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | NOS3 843/4885NOS1 203/4885NOS2 783/4885 |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | CNR1, HSD11B1, HSD17B1 | NOS3 2971/4885NOS1 1464/4885NOS2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.